Sanyou Bio is a biological high-tech enterprise mainly dedicated to the development and service of innovative monoclonal antibody drugs. Recently, Sanyou Bio completed the B+ round of financing of tens of millions of RMB. This round of financing was led by Zijin Hongyun Fund and Huatai Credit Fund under Huatai Zijin. The old shareholders led the additional investment from New Territories Capital, and Qianhai Beizeng Assets and Mr. Xia Guohai participated in the investment. This round of financing will be used to strengthen the construction of an integrated R&D platform for innovative antibody drugs, consolidate the leading edge of the innovative antibody drug discovery platform exceeding trillions of dollars, promote the launch of the intelligent innovative antibody drug discovery platform, and complete the construction of the Phase II base of the R&D center. , and accelerate the development of international business.
This article is reproduced from: https://www.itjuzi.com/investevent/13439760
This site is for inclusion only, and the copyright belongs to the original author.